DRG Market Assessment reports

The triptan drug class dominates the market for approved prescription acute treatments for migraine. Despite the array of approved triptan options, most of them generic, new reformulations have…

According to DRG epidemiology, more than 33 million people in the EU5 suffer from migraines and over 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a core treatment…

According to DRG epidemiology, more than 35 million people in the United States suffer migraines. Migraine prophylaxis, though underused, is a core treatment approach to reduce migraine frequency,…

The migraine market stands on the verge of a renaissance; new and exciting therapies targeting the CGRP peptide could reach the market beginning in 2018. Two broad types of approaches are in final…

According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a core…

According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a…

The triptan drug class dominates the prescription acute treatment migraine market, particularly now that the class is almost fully generic. Despite the array of approved treatment options, new…

The migraine market consists of a multitude of therapies that either acutely treat migraine attacks or serve as prophylactic treatment. Among acute antimigraine therapies, triptans and NSAIDs/…

The acute migraine market is dominated by the oral triptans, although genericization of these agents as well as approvals in recent years of multiple non-oral triptans and non-triptans have begun…

For migraine patients who suffer from 15 or more migraine days per month (chronic migraine) and/or those patients who suffer from long-lasting migraine attacks or do not experience sufficient…

For the estimated 36 million people in the United States who experience migraines, multiple prescription therapies are available that have proved effective in acutely treating migraine pain and its…

Migraine, estimated to affect 36 million people in the United States, is a disabling disease characterized by unilateral or bilateral headache pain that may be accompanied by aura and the…